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Is High-Dose Chemotherapy and Autologous 
Stem Cell Transplantation the Standard Treatment 
for Multiple Myeloma?
For many years, the Alexanian regimen with melphalan and
prednisone (MP) has been considered the standard treatment
for advanced myeloma. The response was about 40%, the
median duration of response 2 years, that of survival 3 years [1].
During recent years, combination regimens containing several
alkylating agents, anthracyclines, and vinca alkaloids have been
evaluated. Many of these regimens have been compared to MP
in randomized studies [2, 3], but no significant difference in
survival was apparent between the two treatments.
However, since 1996 the standard treatment for untreated pa-
tients (and those with limited pretreatment) below 60 years of
age with a good performance status is induction combination
chemotherapy followed by high-dose chemotherapy with autol-
ogous stem cell support.The Intergroupe Français du Myélome
(IFM 90 trial) has recently compared conventional chemo-
therapy with high-dose therapy supported by autologous bone
marrow tansplantation (ABMT) [4]. 200 patients were random-
ized to receive either conventional chemotherapy (18 alter-
nating cycles of polychemotherapy VMCP/VBAP) or high-dose
therapy following 4–6 cycles of VMCP/VBAP. This consisted 
of high-dose melphalan at 140 mg/m2 and total body irradiation
(8 Gy in 4 fractions) followed by ABMT. In this study, the high-
dose treatment was superior to conventional therapy in terms
of overall (81 vs. 57%) and complete (22 vs. 5%) response rates.
The event-free (EFS) 28 vs. 10%) and overall survival (OS) (52
vs. 12%) at 5 years also were significantly superior in the high-
dose arm [5]. In a matched-pair comparison again the high-dose
treatment was demonstrated to provide a superior EFS and OS
when compared to conventional therapy [4].
Should Patients Above the Age of 60 Receive 
High-Dose Therapy?
Several groups [5–7] have shown the feasibility of high-dose
chemotherapy and autologous stem cell transplantation
(ASCT) in selected patients above age 60 with advanced mul-
tiple myeloma, but the improved EFS and OS for high-dose
treatment in the IFM 90 trial could only be confirmed for
patients up to age 60 [4]. Thus, in the German Multiple Mye-
loma Study Group (DSMM) patients between age 60 and 70
are randomized to receive either conventional chemotherapy
or high-dose melphalan treatment followed by ASCT to
assess the efficacy and toxicity of high-dose treatment in this
population. The results of this study should have a great
impact not only for older multiple myeloma (MM) patients,
but also for high-dose therapy studies in other clinical indica-
tions for patients above age 60. At the moment, patients
above 60 years should receive high-dose chemotherapy only
in clinical studies.
How Could the Treatment Results of High-Dose
Therapy be Improved?
Several studies clearly have shown that the better the obtained
post-transplant response, the longer the progression-free
survival (PFS) and OS can be expected. Thus, to improve EFS
and OS the aim must be first to increase the complete remission
(CR) rates beyond the 22% reported in the IFM 90 trial.
Further dose intensification may be achieved by either per-
forming tandem transplants after high-dose melphalan therapy
[8–10] or by an intensified conditioning regimen followed by a
single ASCT [11]. The role of tandem transplantation is being
evaluated in the current IFM 94 trial, which randomizes pa-
tients to either a single or double high-dose procedure follow-
ing induction therapy with VAD [12]. In a first interim analysis
[12], patients showed a better EFS and OS when receiving
double high-dose compared to single high-dose melphalan [12].
The superiority of a double versus a single high-dose regimen
could be further confirmed in an Italian multicenter study [13].
To evaluate an intensified conditioning regimen followed by a
single ASCT, 3 highly active components (irradiation, busulfan,
and cyclophosphamide) were combined in a phase I/II trial [11].
To reduce hepatic and pulmonary toxicity of this intensified
conditioning regimen, a modified total body irradiation (total
marrow irradiation with shielding of liver and lung) and a
reduced dosage of busulfan (12 mg/kg) were administered [14].
With a low transplant-related mortality (1%), the main toxicity
was mucositis WHO grade III/IV, a high rate of CR (50% in
patients with de novo multiple myeloma) could be achieved.
Thus, tandem high-dose melphalan and this intensified con-
ditioning regimen seem to be superior to a single high-dose
melphalan or also a total body irradiation (TBI)/melphalan
regimen. Therefore, in the DSMM patients up to age 60 are
randomized to either receive tandem high-dose melphalan
with double ASCT or an intensified conditioning regimen
consisting of total marrow irradiation/busulfan and cyclophos-
phamide followed by a single ASCT.
What is the Best Time for High-Dose Treatment: 
At Diagnosis or at First Relapse?
Fermand et al. [14] reported the results of a randomized study
comparing early high-dose treatment (HDT) versus late HDT
after relapse following conventional therapy. In the late HDT
arm several cycles of VMCP had been administered up to a
plateau phase (median number of cycles, 7). At progression,
patients received 3–4 cycles of VAMP followed by an inten-
sified treatment combining TBI (12 Gy), cyclophosphamide 
(60 mg/kg), melphalan (140 mg/m2) and etoposide (500 mg/m2)
supported by ASCT. In the early HDT arm, patients received
3–4 cycles of VAMP followed by the same intensive HDT as in
case of late HDT. In both groups, autologous peripheral stem
cells were collected at diagnosis after mobilization by CHOP.
After HDT, all patients were proposed an interferon treat-
ment. After a median follow-up of 42 months, the overall sur-
vival was not different in the two arms. The authors showed
that time without symptoms and treatment (23 vs.17 months in
the early and late arm, respectively), as well as treatment toxi-
city were different in the two arms. The median survival post-
transplantation was better in the early arm versus the late arm
(61 vs. 28 months, respectively). Despite of the same OS, the
authors recommended HDT in symptomatic MM patients
early in the course of the disease.
When Should an Allogeneic Stem Cell 
Transplantation be Performed?
In younger patients (< 55 years), the therapeutic decision is
also dependent on whether allogeneic bone marrow transplan-
tation is an option or not. Tricot et al. [15] have reported the
existence of a graft-versus-myeloma effect and this was in part
confirmed by Björkstrand et al. [16]. In this European Blood
and Marrow Transplantation Study matched-case study [16],
the results of allogeneic bone marrow transplantation were
compared to those following ABMT.The OS (34 vs.18 months)
and PFS were better in the autologous arm, but the difference
was only apparent in male patients. The relapse and progres-
sion rate were significantly higher in autologous patients 
(2-year-relapse/progression rate 70 vs. 50%), whereas the
treatment-related mortality was higher in allogeneic patients
(41 vs. 13%). However, if only patients alive 1 year after trans-
plantation were analyzed, PFS was better in the allogeneic arm
(41 vs. 24 months). This study indicates that allogeneic bone
marrow transplantation is more toxic but possibly more effec-
tive than autologous stem cell transplantation. There is no con-
sensus advocating allogeneic or autologous transplantation in
MM patients aged less than 55 years old with a sibling donor.
It is a difficult situation in which a high risk of toxicity-related
death must be weighed against higher efficacy. In the DSMM
thus patients below age 55 – when an HLA-identical sibling
donor is available – are offered allogeneic or autologous stem
cell transplantation. Both patient groups receive the same
induction and conditioning therapy, thus allowing to assess
risks and benefits of allogeneic compared to autologous stem
cell transplantation.
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